Follow-On Biologics Legislation Could Come Down to Horse-Trading
This article was originally published in The Pink Sheet Daily
Executive Summary
Length of brand exclusivity may depend on concession more than reasoned argument, Genzyme’s Holcombe predicts.
You may also be interested in...
Follow-on Biologics Savings Lower In Administration’s Budget Proposal
FOB pathway would create only $6.35 billion in savings, according to the budget, down from the $9.24 billion projected in February.
Forest Files Memantine/Donepezil Fixed Combination For Alzheimer’s
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.
Alzheimer’s, BRAIN Initiative Highlighted In $30 Billion NIH Budget Proposal
President Obama’s proposed $56 billion Opportunity, Growth and Security Initiative would add nearly $1 billion to the NIH budget but it is funded by offsets that are likely nonstarters in Congress.